Goldman Sachs Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $27
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Johnson initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $27.
February 20, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs initiated coverage on ArriVent BioPharma with a Buy rating and set a price target of $27.
The initiation of coverage by a major financial institution like Goldman Sachs, especially with a Buy rating and a significant price target, is typically seen as a positive signal to the market. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100